Cow Milk Protein AllergyNCT07242950
Effect of Elimination Diet on Intestinal Mucus Barrier in Infants With Cow's Milk Protein Allergy
An observational study of Cow Milk Protein Allergy and Mucin, run by Baskent University at 1 site in Turkey (Türkiye).
Trial summary
The goal of this observational study is to learn about the effects of cow's milk protein elimination diets on breastfed infants under 26 weeks of age with newly diagnosed non-IgE-mediated CMPA. Read more about this study
- Who is it for?
- Ages 1 week to 26 weeksHealthy volunteers can take part
- Conditions the study is for
- Cow Milk Protein Allergy, Mucin, Immunoglobulin A
- How many people
- 34 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 4 Sep 2023to 30 Aug 2024
- How long will I take part?
- 3 Months
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 week to 26 weeks
- All sexes
- Healthy volunteers accepted
- Child
Study population: The study included breastfed babies under 26 weeks of age who were diagnosed with new non-IgE-mediated CMPA by an allergist, had an elimination diet, and applied to two hospitals designated in Türkiye. Infants and their mothers without allergies or atopic diseases, similar in age and gender, were in the control group.
Who may be able to join
- Diagnosed with non-IgE-mediated ARI during the study period,
- Aged less than 26 weeks at the beginning of the study,
- Still breastfeeding,
- Gestational age between 37 and 42 weeks,
- Single birth,
- Birth weight ≥ 2500 g and ≤ 4500 g, and their mothers.
Show all 17Show fewer
- The exclusion criteria for the case group are as follows:
- those with a diagnosed chronic or systemic disease, those with neonatal disease or congenital malformation, those who have had an infection or illness requiring hospitalisation during the study period, infants who have never been breastfed and their mothers.
- Age less than 26 weeks at the beginning of the study,
- No allergy to food or medication,
- No diagnosis of an atopic disease,
- Still breastfeeding,
- Gestational age between 37 and 42 weeks,
- Single birth,
- Infants with birth weight ≥ 2500 g and ≤ 4500 g and their mothers.
- The exclusion criteria for the control group are as follows:
- Those with a diagnosed allergy or atopic disease, those with a diagnosed known chronic or systemic disease, those with neonatal disease or congenital malformations, those who have experienced an infection or illness requiring hospitalisation during the study period, infants who have never received breast milk and their mothers.
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of the Effect of Elimination Diet on Intestinal Mucus Barrier in Infants Diagnosed With Cow's Milk Protein Allergy
The goal of this observational study is to learn about the effects of cow's milk protein elimination diets on breastfed infants under 26 weeks of age with newly diagnosed non-IgE-mediated CMPA. The main question it aims to answer is:
Does a cow's milk protein elimination diet improve clinical symptoms (CoMiSS scores), growth parameters, and gut immune markers (MUC2 and sIgA) in breastfed infants with CMPA?
Participants included breastfed infants under 26 weeks diagnosed with non-IgE-mediated CMPA and healthy age- and sex-matched controls without allergies. Infants and their mothers were followed prospectively. Data were collected at baseline and at the end of the study through face-to-face surveys with mothers, three-day food records, anthropometric measurements, CoMiSS evaluations, and stool samples. Mothers in the CMPA group received education on elimination diets, calcium supplementation, and complementary feeding guidance, while the control group received only complementary feeding guidance. Stool samples were analyzed for MUC2 and sIgA using ELISA.
Read the detailed description
The study included breastfed babies under 26 weeks of age who were diagnosed with new non-IgE-mediated CMPA by an allergist, had an elimination diet, and applied to two hospitals designated in Türkiye. Infants and their mothers without allergies or atopic diseases, similar in age and gender, were in the control group. According to the power analysis performed with G*Power, a total of 32 infants were needed to detect a medium-sized difference with a 5% type I error rate and 85% power. The study began with 20 infants with CMPA and 18 healthy infants. Following dietary noncompliance and withdrawals, the study concluded with 17 infants in each group.
Data were collected at two time points: the beginning and end of the study. At each point, face-to-face surveys were administered to mothers, three-day food records were obtained for both mothers and infants, and infants' anthropometric measurements, Cow's Milk Protein-related Symptom Scores (CoMiSS), and stool samples were collected.
Mothers in the case group received detailed training on cow's milk protein (CMP) elimination diets and complementary feeding and were supplemented with 1000 mg/day of calcium. The control group received only complementary feeding guidance. Monthly follow-ups were conducted to monitor compliance. The elimination diet in the case group was prescribed and supervised by a dietitian, with reintroduction following the "milk ladder" protocol after an average of 1.9±0.79 months. In the control group, final assessments were performed three months after baseline. At study completion, all initial measurements were repeated, and a second stool sample was collected.
Infants' body weight (kg), length (cm) and head circumference (cm) measurements were taken by a physician using a standardized scale, infantometer and non-stretch tape measure, in accordance with the method recommended by the World Health Organisation. Anthropometric measurements [length-for-age (LFA), weight-for-age (WFA), weight-for-length (WFL) and head circumference-for-age (HCFA)] were assessed using the WHO ANTHRO Software according to Z-scores (z-score=patient's value-mean value/standard deviation).
Three-day food records (two weekdays, one weekend day) were collected from mothers and infants. Mothers' records were used to assess adherence to the elimination diet, and participants consuming dairy during the diet were excluded. Portion sizes were estimated using a portion size picture book. Daily energy and nutrient intakes were analyzed using BeBiS software (version 9.0). Infants' intakes were evaluated against Adequate Intake (AI) reference values from the Dietary Reference Intakes (DRI). Breast milk intake was estimated using the ALSPAC method: 100 mL for feeds >10 minutes and 50 mL for feeds <5 minutes, with reference values of 780 mL/day for 0-6 months and 600 mL/day for 7-12 months.
The clinical symptoms of infants were assessed using CoMiSS. CoMiSS is a scoring system that assesses crying, regurgitation, stool type (Bristol stool scale), skin and respiratory symptoms, with a total score ranging from 0 to 33.
Stool samples were collected in a container with a spoon at the beginning and end of the study to ensure an adequate quantity (≥50 mg) was obtained. The samples were stored at -80°C to prevent loss of bioactivity and contamination. MUC2 and sIgA analyses were performed using the sandwich enzyme immunoassay method with Human MUC2 and Human sIgA ELISA kits via the enzyme-linked immunosorbent assay (ELISA) method. The Human MUC2 ELISA kit has a sensitivity of 0.57 ng/mL and a measurement range of 1.57-100 ng/mL. The Human sIgA ELISA kit has a sensitivity of 0.098 µg/mL and a measurement range of 0.312-20 µg/mL. According to the analysis protocol, samples and standards were added in duplicate to microtiter wells. Then, biotin-conjugated specific antibody and avidin-HRP conjugate were applied. After the color developed with the TMB substrate, the reaction was stopped with a stop solution containing sulfuric acid. Absorbance was measured at a wavelength of 450±10 nm. Concentrations were then calculated using a standard curve based on the obtained optical density values.
- Conditions
- Cow Milk Protein Allergy, Mucin, Immunoglobulin A, Diet Therapy
- Keywords
- Cow Milk Protein Allergy, Mucin-2, Secretory Immunoglobulin A, Elimination Diet
- Medical subject headings
- Medullary cystic kidney disease 1
What is being measured
The primary outcome is the main question the study is designed to answer.
MUC2 level
Measured: From the day of CMPA diagnosis in infants until three months later in case group From the beginning the study in infants until three months later in control group
sIgA level
Measured: From the day of CMPA diagnosis in infants until three months later in case group From the beginning the study in infants until three months later in control group
Secondary outcomes (1)
Monitoring of growth
Measured: From the day of CMPA diagnosis in infants until three months later in case group From the beginning the study in infants until three months later in control group
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Nov 2025
- Study start4 Sep 2023
- Primary completion4 Oct 2023
- Study completion30 Aug 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cow Milk Protein AllergyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 34 participants (actual)
- Target duration
- 3 Months
Sponsor and investigators
- Lead sponsor
- Baskent University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07242950
- Sponsor's protocol ID
- KA23/257
- Status last verified
- Nov 2025
- First submitted
- 19 Sep 2025
- Last updated
- 21 Nov 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Data obtained through this study may be provided to qualified researchers with academic interest on CMPA. Data or samples shared will be coded, with no PHI included. Approval of the request and execution of all applicable agreements (i.e. a material transfer agreement) are prerequisites to the sharing of data with the requesting party.
Study at a glance
From the registry record, last updated by the sponsor on 21 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Effect of Elimination Diet on Intestinal Mucus Barrier in Infants Diagnosed With Cow's Milk Protein Allergy
- ClinicalTrials.gov ID
- NCT07242950
- Acronym / sponsor ID
- KA23/257
- Conditions
- Cow Milk Protein Allergy, Mucin, Immunoglobulin A, Diet Therapy
- Keywords
- Cow Milk Protein Allergy, Mucin-2, Secretory Immunoglobulin A, Elimination Diet
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 34 participants (actual)
- Lead sponsor
- Baskent UniversityUniversity, hospital or other
- Study start
- 4 Sep 2023 (actual)
- Primary completion
- 4 Oct 2023 (actual)
- Study completion
- 30 Aug 2024 (actual)
- First posted
- 21 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn about the effects of cow's milk protein elimination diets on breastfed infants under 26 weeks of age with newly diagnosed non-IgE-mediated CMPA. The main question it aims to answer is:
Does a cow's milk protein elimination diet improve clinical symptoms (CoMiSS scores), growth parameters, and gut immune markers (MUC2 and sIgA) in breastfed infants with CMPA?
Participants included breastfed infants under 26 weeks diagnosed with non-IgE-mediated CMPA and healthy age- and sex-matched controls without allergies. Infants and their mothers were followed prospectively. Data were collected at baseline and at the end of the study through face-to-face surveys with mothers, three-day food records, anthropometric measurements, CoMiSS evaluations, and stool samples. Mothers in the CMPA group received education on elimination diets, calcium supplementation, and complementary feeding guidance, while the control group received only complementary feeding guidance. Stool samples were analyzed for MUC2 and sIgA using ELISA.
Detailed description
The study included breastfed babies under 26 weeks of age who were diagnosed with new non-IgE-mediated CMPA by an allergist, had an elimination diet, and applied to two hospitals designated in Türkiye. Infants and their mothers without allergies or atopic diseases, similar in age and gender, were in the control group. According to the power analysis performed with G*Power, a total of 32 infants were needed to detect a medium-sized difference with a 5% type I error rate and 85% power. The study began with 20 infants with CMPA and 18 healthy infants. Following dietary noncompliance and withdrawals, the study concluded with 17 infants in each group.
Data were collected at two time points: the beginning and end of the study. At each point, face-to-face surveys were administered to mothers, three-day food records were obtained for both mothers and infants, and infants' anthropometric measurements, Cow's Milk Protein-related Symptom Scores (CoMiSS), and stool samples were collected.
Mothers in the case group received detailed training on cow's milk protein (CMP) elimination diets and complementary feeding and were supplemented with 1000 mg/day of calcium. The control group received only complementary feeding guidance. Monthly follow-ups were conducted to monitor compliance. The elimination diet in the case group was prescribed and supervised by a dietitian, with reintroduction following the "milk ladder" protocol after an average of 1.9±0.79 months. In the control group, final assessments were performed three months after baseline. At study completion, all initial measurements were repeated, and a second stool sample was collected.
Infants' body weight (kg), length (cm) and head circumference (cm) measurements were taken by a physician using a standardized scale, infantometer and non-stretch tape measure, in accordance with the method recommended by the World Health Organisation. Anthropometric measurements [length-for-age (LFA), weight-for-age (WFA), weight-for-length (WFL) and head circumference-for-age (HCFA)] were assessed using the WHO ANTHRO Software according to Z-scores (z-score=patient's value-mean value/standard deviation).
Three-day food records (two weekdays, one weekend day) were collected from mothers and infants. Mothers' records were used to assess adherence to the elimination diet, and participants consuming dairy during the diet were excluded. Portion sizes were estimated using a portion size picture book. Daily energy and nutrient intakes were analyzed using BeBiS software (version 9.0). Infants' intakes were evaluated against Adequate Intake (AI) reference values from the Dietary Reference Intakes (DRI). Breast milk intake was estimated using the ALSPAC method: 100 mL for feeds >10 minutes and 50 mL for feeds <5 minutes, with reference values of 780 mL/day for 0-6 months and 600 mL/day for 7-12 months.
The clinical symptoms of infants were assessed using CoMiSS. CoMiSS is a scoring system that assesses crying, regurgitation, stool type (Bristol stool scale), skin and respiratory symptoms, with a total score ranging from 0 to 33.
Stool samples were collected in a container with a spoon at the beginning and end of the study to ensure an adequate quantity (≥50 mg) was obtained. The samples were stored at -80°C to prevent loss of bioactivity and contamination. MUC2 and sIgA analyses were performed using the sandwich enzyme immunoassay method with Human MUC2 and Human sIgA ELISA kits via the enzyme-linked immunosorbent assay (ELISA) method. The Human MUC2 ELISA kit has a sensitivity of 0.57 ng/mL and a measurement range of 1.57-100 ng/mL. The Human sIgA ELISA kit has a sensitivity of 0.098 µg/mL and a measurement range of 0.312-20 µg/mL. According to the analysis protocol, samples and standards were added in duplicate to microtiter wells. Then, biotin-conjugated specific antibody and avidin-HRP conjugate were applied. After the color developed with the TMB substrate, the reaction was stopped with a stop solution containing sulfuric acid. Absorbance was measured at a wavelength of 450±10 nm. Concentrations were then calculated using a standard curve based on the obtained optical density values.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Target follow-up
- 3 Months
Who may qualify
- Ages
- 1 week to 26 weeks
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
- Study population
- The study included breastfed babies under 26 weeks of age who were diagnosed with new non-IgE-mediated CMPA by an allergist, had an elimination diet, and applied to two hospitals designated in Türkiye. Infants and their mothers without allergies or atopic diseases, similar in age and gender, were in the control group.
Key inclusion criteria (17 listed)
- Diagnosed with non-IgE-mediated ARI during the study period,
- Aged less than 26 weeks at the beginning of the study,
- Still breastfeeding,
- Gestational age between 37 and 42 weeks,
- Single birth,
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
MUC2 level
Time frame: From the day of CMPA diagnosis in infants until three months later in case group From the beginning the study in infants until three months later in control group
sIgA level
Time frame: From the day of CMPA diagnosis in infants until three months later in case group From the beginning the study in infants until three months later in control group
1 secondary outcome
Monitoring of growth
Time frame: From the day of CMPA diagnosis in infants until three months later in case group From the beginning the study in infants until three months later in control group
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Nov 2025.
- Individual participant dataSharing planned: Yes. Data obtained through this study may be provided to qualified researchers with academic interest on CMPA. Data or samples shared will be coded, with no PHI included. Approval of the request and execution of all applicable agreements (i.e. a material transfer agreement) are prerequisites to the sharing of data with the requesting party.
Related trials for Cow Milk Protein Allergy
Recruiting
Evaluation of the Tolerance of a New Formula Based on Hydrolyzed Rice Proteins in Children With Cow's Milk Allergy
IgE-Mediated Cow Milk Allergy
Not yet recruiting
TeriFort 1+ Study: Efficacy and Safety of an Extensively Hydrolyzed Formula in the Management of Cow's Milk Protein Allergy in Young Children: A Prospective, Single-Arm Interventional Study (TeriFort 1+)
Cow's Milk Protein Allergy (CMPA)
Not yet recruiting
GOAt Milk Formula-based Ladder Versus Cow's Milk Ladder
Food Allergy, Cow's Milk Protein Allergy
Not yet recruiting
Dietary Restriction Efficiency Assessment in CMPA
Cow's Milk Protein Allergy
Not yet recruiting
Growth And Safety Outcomes In Infants With Cow´s Milk Protein Allergy (CMPA) Fed A Novel Extensively Hydrolyzed Formula (eHF)
Cow Milk Protein Allergy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cow Milk Protein Allergy and Mucin, run by Baskent University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 17 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MUC2 level (time frame: From the day of CMPA diagnosis in infants until three months later in case group From the beginning the study in infants until three months later in control group). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Nov 2025.